Cerebrolysin vs Noopept

Standardized mixture of neuropeptides derived from porcine brain proteins; mimics endogenous neurotrophic factors (BDNF, NGF, CNTF); promotes neurogenesis and synaptic plasticity

Cerebrolysin is a brain-derived polypeptide preparation derived from porcine cortical tissue, composed of low-molecular-weight neuropeptides and free amino acids that cross the blood-brain barrier and exert neurotrophic and neuroprotective effects. It is proposed to mimic endogenous neurotrophic factors, supporting neuronal survival, synaptic plasticity, and metabolic activity in damaged or degenerating brain tissue through multiple growth factor-like pathways. A Cochrane systematic review and multiple controlled clinical trials from Eastern European research groups have evaluated cerebrolysin for vascular dementia and stroke-related cognitive impairment, with mixed results that suggest potential benefit in specific post-stroke populations. Cerebrolysin is not FDA-approved; it is approved and widely used in Russia, Eastern Europe, and some Asian countries as a prescription neuroprotective treatment, and its evidence base reflects predominantly Eastern European clinical methodology with variable trial quality. Cerebrolysin price and access: Cerebrolysin is not available through standard US pharmacy channels; it is a prescription medication in the countries where it is approved (Russia, Eastern Europe, China, South Korea, and others) and is not FDA-approved. In markets where it is approved, cerebrolysin is administered intravenously in clinical settings — IV infusion courses of 10–20 sessions are the standard research and clinical protocol, with treatment costs varying significantly by country and clinic. Importation for personal use exists in a legal grey area in the United States; some wellness and peptide clinics may offer cerebrolysin as part of supervised protocols. Cancer-adjacent research: cerebrolysin's neurotrophic properties have drawn preclinical research interest in the context of chemotherapy-induced cognitive impairment (chemobrain), where neuroprotection during and after oncology treatment is a research priority. Autism spectrum disorder research: small controlled trials from Eastern European groups have evaluated cerebrolysin for speech and behavioral development in children with ASD, with mixed results; this remains an exploratory research area with no established clinical consensus. Stroke rehabilitation remains cerebrolysin's strongest evidence base, with multiple controlled trials evaluating cognitive and functional recovery in post-stroke patients.

Prodrug converting to cycloprolylglycine; modulates AMPA and NMDA receptors; increases NGF and BDNF expression

Noopept (GVS-111) is a synthetic dipeptide nootropic studied primarily in Russia and Eastern Europe as a cognitive enhancer and neuroprotectant, structurally derived from the endogenous cycloprolylglycine neuropeptide and related to the racetam family. It is proposed to modulate AMPA receptor sensitivity, enhance alpha-7 nicotinic acetylcholine receptor activity in hippocampal interneurons, and increase expression of NGF and BDNF, potentially supporting synaptic plasticity and memory consolidation. Russian clinical trials in patients with mild cognitive impairment following stroke have reported improvements in cognitive scores, while preclinical studies have characterized its cellular mechanisms in hippocampal preparations. Noopept is sold as a dietary supplement or nootropic in some jurisdictions and classified as a prescription drug in others; it has not received FDA approval and is not approved by the EMA. Noopept nasal spray and delivery routes: Noopept is studied across multiple delivery routes, with nasal spray emerging as a popular administration method due to the olfactory-to-brain pathway that bypasses first-pass metabolism and delivers the compound more directly to the central nervous system. Noopept nasal spray formulations are used in research contexts as an alternative delivery route; no standardized intranasal dosing protocol has been established. Sublingual administration has also been explored for similar bioavailability advantages over oral dosing. Oral capsules remain the most common form in research contexts, with typical study doses ranging from 10–30mg per day across Russian clinical research. Anxiety and stress resilience are among the secondary research areas for Noopept beyond its primary cognitive enhancement profile — its anxiolytic effects have been observed in preclinical studies, attributed in part to its modulation of the GABAergic system and BDNF upregulation. Sleep architecture effects and ADHD-adjacent attentional improvements have also been noted anecdotally in research user communities, though controlled trial data for these applications is limited. Noopept is a research compound; no approved dosing guidelines exist outside its Russian prescription context.